For decades, cancer has survived by mastering disguise. It changes shape, rewires signals, and learns how to stay invisible to the body’s natural defenses. Even as science has delivered powerful immunotherapies that train immune cells to attack tumours, many patients still hear the same hard truth: the treatment works for some, but not for all. Now, a discovery from researchers at MIT and Stanford University suggests that cancer’s invisibility cloak may finally be tearing and the thread holding it together is something as simple, and as complex, as sugar.

Cancer cells are not just abnormal because they divide uncontrollably. They are abnormal because they communicate differently. One of the most overlooked ways they do this is through glycans, tiny sugar molecules that coat the outer surface of cells. In healthy tissue, glycans help cells interact normally with their surroundings. In cancer, these same sugar structures are altered and weaponised. Tumours use them to send false “do not attack” signals to the immune system, effectively applying a biological brake that prevents immune cells from recognising danger.

Immunotherapy has already shown that releasing certain brakes can change lives. Drugs that block the PD-1 and PD-L1 pathway have transformed cancer care by allowing immune cells, especially T cells, to strike tumours that once went undetected. Some patients experience long-lasting remission. Others see little benefit at all. This uneven success has driven scientists to ask a deeper question: how many other brakes does cancer use to slow the immune system down?

The answer, it turns out, may lie in sugars that most people never think about.

The new research, led by Jessica Stark in collaboration with Carolyn Bertozzi, reveals a way to disable a powerful immune escape route that tumours rely on. Their work, published in Nature Biotechnology, focuses on sialic acids which is a type of glycan found in unusually high amounts on the surface of many cancer cells.

These sialic acids interact with receptors on immune cells called Siglecs. When this binding happens, immune cells receive a strong inhibitory signal. Instead of attacking the tumour, they hesitate, retreat, or remain inactive. It is a clever trick. The immune system sees sugar patterns it interprets as “self” and stands down, even when those sugars are sitting on malignant cells.

Until now, this pathway has been extremely difficult to block in a meaningful way. Scientists have tried designing molecules that stick to sialic acids and prevent them from sending suppressive signals. The problem is scale and strength. Lectins, the molecules that bind sugars, do not attach firmly enough on their own. They drift away before making a real difference.

The breakthrough came when researchers stopped treating lectins as solo agents and instead paired them with something cancer already understands very well: antibodies.

By engineering hybrid proteins known as AbLecs, the team fused a lectin with an antibody designed to target tumour-specific markers. The antibody acts like a guided missile, taking the lectin directly to the cancer cell surface. Once anchored there, the lectin blocks sialic acids from engaging with immune cell receptors. The brake is released. The immune system moves again.

What makes this discovery particularly striking is its elegance. Instead of inventing an entirely new drug class from scratch, the researchers adapted tools already familiar to oncology. Antibodies like trastuzumab, rituximab, and cetuximab are well-known cancer therapies. By modifying their structure, scientists created a modular platform that can be customised for different cancers, immune pathways, and patient needs.

In laboratory studies, immune cells exposed to these AbLecs showed renewed aggression toward cancer cells. Macrophages and natural killer cells, both critical players in innate immunity, became more active. They recognised tumour cells as threats and destroyed them with greater efficiency. This effect was not subtle. It represented a clear shift from immune silence to immune engagement.

The results were even more compelling in animal models. Mice engineered to carry human immune receptors developed lung metastases after being injected with cancer cells. Those treated with the AbLec therapy showed a marked reduction in metastatic burden compared to mice receiving standard antibody treatment alone. In simple terms, the immune system was no longer being fooled by sugar-coated deception.

This matters because metastasis, not the original tumour, is responsible for the majority of cancer-related deaths. Any therapy that reduces the spread of cancer, while harnessing the body’s own defences, carries enormous clinical promise.

The implications extend far beyond one type of cancer or one patient group. Glycan-based immune suppression appears across many tumour types, from breast and colorectal cancers to blood malignancies. By targeting this shared mechanism, AbLecs could complement existing immunotherapies and widen the pool of patients who benefit from immune-based treatment.

There is another reason this research stands out in today’s crowded oncology landscape. Many cancer therapies are powerful but punishing. They attack tumours aggressively while damaging healthy tissue. Immunotherapy shifted that balance by working with the immune system instead of against it. Yet immune-related side effects remain a concern. The glycan-Siglec pathway offers a more selective target. Tumour-specific glycans are far less common on healthy cells, raising hope for effective treatment with fewer unintended consequences.

This approach also reflects a deeper shift in how scientists think about cancer biology. For years, genes and proteins dominated the conversation. Sugars were seen as decorative, secondary, or too complex to study. That view is changing. Glycobiology is now emerging as one of the most promising frontiers in medical science. The surface chemistry of cells is proving to be just as important as the DNA inside them.

In practical terms, the AbLec platform is designed for flexibility. Researchers can swap one antibody for another to match different tumour markers. They can change the lectin component to block different immune-suppressive sugars. They can even combine glycan targeting with traditional checkpoint inhibition. This adaptability makes the technology especially attractive for precision medicine, where treatment is tailored to the biology of an individual patient’s cancer.

For patients who do not respond to current checkpoint inhibitors, this discovery could open a new door. It suggests that immune failure is not always due to weak immune cells, but often due to clever tumours that know how to hide. Remove the disguise, and the immune system may already have what it needs to fight back.

The broader message is equally important. Cancer research does not always advance through dramatic, headline-grabbing revolutions. Sometimes progress comes from understanding something we have overlooked for years. Sugars are everywhere in biology. They shape how cells talk, stick, grow, and survive. By paying attention to them, scientists have uncovered a vulnerability that cancer has long relied on.

While AbLec therapies are still in early stages and will require extensive clinical testing, the concept itself marks a turning point. It challenges the idea that immunotherapy has reached its limits. Instead, it suggests that the immune system still has untapped potential, waiting to be unlocked by smarter design.

For healthcare systems worldwide, including those facing rising cancer burdens and limited resources, such innovations matter deeply. Treatments that enhance existing drugs rather than replace them can be more cost-effective and faster to deploy. They can integrate into current care pathways instead of disrupting them entirely.
and
At its core, this research reminds us that cancer’s greatest strength has always been deception. It survives by convincing the body that it belongs. By stripping away that illusion, science is giving the immune system permission to do what it evolved to do: protect, defend, remember.

If these sugar-based brakes can truly be released in humans, the future of cancer therapy may look very different. It may rely less on brute force and more on clarity. Less on poisoning disease and more on revealing it. In that future, the immune system does not need to be taught how to fight cancer. It simply needs to be allowed to see it.